Breaking News

Regulus Therapeutics Appoints CBO and General Counsel

By Kristin Brooks | February 4, 2014

Szekeres to lead business development and legal efforts

David Szekeres has been appointed chief business officer and general counsel at Regulus Therapeutics, Inc. Mr. Szekeres will be responsible for leading business development, strategic planning and legal efforts, and will serve as a key member of its executive leadership team.
 
Most recently, Mr. Szekeres served as deputy general counsel, chief M&A counsel and assistant secretary at Life Technologies Corp., where he led more than fifty transactions valued at more than $30 billion, including the merger of Applied Biosystems and Invitrogen in 2008 and the acquisition of Life by Thermo Fisher Scientific in 2013. Mr. Szekeres was responsible for all legal functions in the areas of corporate transactions, corporate governance, SEC reporting and compliance, and was responsible for expanding Life's diagnostics business with several strategic acquisitions.  
 
"We are very pleased to welcome David to our Regulus team at such an exciting time for the company," said Kleanthis G. Xanthopoulos, Ph.D., president and chief executive officer of Regulus. "David's involvement with transformative strategic transactions and overall operational experience at Life will add both depth and strategic capabilities to our well rounded team as we continue to build Regulus into a top-tier biopharmaceutical company. We are dedicated to RNA therapeutics and to leading the discovery and development of a new and major class of medicines targeting microRNAs."

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity